No Prescription |
 |
 | ||
|
Virenza with Revolizer Relenza |
|
| ||
No Prescription » Prescription Drugs 17 » Virenza with Revolizer Relenza Zanamivir is used in adults and children at least 7 years of age to treat some types of influenza ('flu') in people who have had symptoms of the flu for less than 2 days. This medication is also used to prevent some types of flu in adults and children at least 5 years of age when they have spent time with someone who has the flu or when there is a flu outbreak. Zanamivir is in a class of medications called neuraminidase inhibitors. It works by stopping the growth and spread of the flu virus in your body. Zanamivir helps shorten the time you have flu symptoms such as nasal congestion sore throat cough muscle aches tiredness weakness headache fever and chills. Buy Virenza with Revolizer Relenza and other Prescription Drugs 17 products online at Medstore. Buy Online at Medstore - Click Here!
About Virenza with Revolizer Relenza: Product Type: Prescription Drugs 17 Virenza with Revolizer (Relenza Generic Zanamivir) Virenza with Revolizer (Relenza Generic Zanamivir) Relenza Generic Zanamivir 5mg Relenza Generic Zanamivir Virenza with Revolizer
View more Prescription Drugs 17 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
